The first endovascular neural interface, the Stentrode™ is a minimally invasive implantable brain device that can interpret signals from the brain for patients with paralysis. Implanted via the jugular vein, the #Stentrode is placed inside the #brain in the command-control center, known as the motor cortex, but without the need for open brain surgery. The signals are captured and sent to a wireless unit implanted in the chest, which sends them to an external receiver. We are building a software suite that enables the patient to learn how to control a computer operating system and set of applications that interact with assistive technologies. This #technology has the potential to enable patients with paralysis to take back digital control of their world, without having to move a muscle.
Synchron is currently preparing for pilot clinical trials of the Stentrode™ to evaluate the safety and efficacy of this breakthrough technology.
Find out more at:
synchronmed.com.
https://twitter.com/synchron_ss
Comments are closed.